(TSXV: SEGN), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced that its Chief Executive Officer, Elad Bibi-Aviv, will host two virtual investor meetings on January 19, 2026. These online sessions will provide shareholders with an opportunity to meet Mr. Bibi-Aviv personally and hear his vision for Seegnal’s future. In each meeting he will introduce himself, outline the Company’s strategic direction, and answer questions from investors, fostering direct dialogue with the shareholder community.
For convenience, the first session will be conducted in the Hebrew language and the other in English. The Hebrew meeting is scheduled for January 19, 2026, from 7:00 to 8:00 PM Israel Standard Time (IST), and the English meeting from 1:30 to 2:30 PM Eastern Standard Time (EST) on the same day. Both meetings will be held via Microsoft Teams Meeting (links provided below).
Mr. Bibi-Aviv has emphasized that Seegnal’s purpose-driven mission was a key motivator in joining the Corporate as Chief Executive Officer, and stated ‘I joined Seegnal because I recognize it as a genuine opportunity to make a real impact — a mission I find deeply meaningful,’ he said. ‘As demonstrated in the publication in The American Journal of Pharmacy Benefits, Vol. 9, No. 2 titled ‘Large-Scale, Community-Based Trial of a Personalized Drug-Related Problem Rectification System’ and in the publication in Drug Safety, Vol.44: 661-668 titled ‘Reducing Alert Fatigue While Improving Safety – Comparison of Medication Alerts from Two Commercial Applications in the USA’, the technology we have developed not only saves lives but also delivers significant economic value to healthcare organizations, hospitals, and insurance companies worldwide.’ Mr. Bibi-Aviv invites shareholders to regard themselves as partners in this journey and encourages them to ask questions freely. Seegnal encourages all current and potential shareholders to attend these sessions.
Meeting Details
On the Agenda:
- Personal introduction
- Company update and strategic outlook
- Open Q&A
About Seegnal
Seegnal (TSXV:SEGN) aims to solve one of the top causes of death and injuries in the modern world – Adverse Drug Effects (ADEs). Seegnal’s Clinical Decision Support system introduces a paradigm shift in the approach to this problem by implementing a new elevated Patient-Centric Standard. Seegnal’s SaaS technology exclusively integrates, at the point-of-care, unique patient-specific data such as genetics, lab results, ECG, smoking status, allergies, food interactions, gender, age, and the effects of many concomitant medications, while reducing the current alert load for clinicians by over 90%. In practice, clinicians using Seegnal eHealth complete their prescription workflow with limited interruption, saving time and fatigue. Patients enjoy more tailored medication and improved safety, leading to better quality of life, with precision alerts reaching up to 98% accuracy. Institutions have reported reductions in admissions, medication consumption, and significant time savings in prescription renewals. Seegnal eHealth is marketing its SaaS-based platform in Israel (where the Ministry of Health recently adopted Seegnal’s patient-specific standard as the new standard in governmental hospitals), the United Arab Emirates, the United Kingdom, the United States, and Poland. The platform is currently a ‘standard of care’ system for over 10,000 clinicians in Israel, used daily for prescribing medications.
See www.seegnal.com.
Cautionary Note Regarding Forward-Looking Information
This press release contains ‘forward-looking information’ or ‘forward-looking statements’ within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, including statements included in the ‘About Seegnal’ section of this press release, are forward-looking. Generally, the forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as ‘anticipate’, ‘believes’, ‘estimates’, ‘expects’, ‘intends’, ‘may’, ‘should’, ‘will’ or variations of such words or similar expressions. More particularly, and without limitation, this press release contains forward-looking information or forward-looking statements concerning Seegnal’s anticipated introductory videocalls with Mr. Bibi-Aviv. These statements are based on current assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to Seegnal’s public filings with applicable securities regulators for additional information regarding risk factors and other disclosures.
Seegnal cautions that all forward-looking information and forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of Seegnal, including expectations and assumptions concerning Seegnal and its products as well as other risks and uncertainties, including those described in Seegnal’s filings available on SEDAR+ at www.sedarplus.ca. The reader is cautioned that assumptions used in the preparation of any forward-looking information or forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of Seegnal. The reader is cautioned not to place undue reliance on any forward-looking information or forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking information and forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Seegnal does not undertake any obligation to update publicly or to revise any of the included forward-looking information or forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Source
